DFX Intelligence
Private Equity Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Equity Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Firms / A••••••••• M••••••••• I•••
A••••••••• M••••••••• I•••
We are A•••••••••, a trans-atlantic bio-science investment firm with a deep understanding of both the science and markets we invest in.
Classification
- Class
- Buyout firmconfirmed, confidence 85%
- Basis
- R6: 9 of 17 distinct vehicles are sworn Private Equity Funds; 10 reported gross assets on a filing in 2022 or later
- Size band
- Middle marketdefined by: proxy: $1.73bn Private Equity Fund GAV on the Form ADV filed 2022-10-31
Classification history (3)
- Sep 16, 2026Buyout firm (confirmed, 85%, cls-pe-2)R6: 9 of 17 distinct vehicles are sworn Private Equity Funds; 10 reported gross assets on a filing in 2022 or later
- Sep 16, 2026Buyout firm (confirmed, 85%, cls-pe-2)R6: 9 of 17 distinct vehicles are sworn Private Equity Funds; 10 reported gross assets on a filing in 2022 or later
- Sep 13, 2026Buyout firm (confirmed, 85%, cls-pe-1)R6: 9 of 17 distinct vehicles are sworn Private Equity Funds; 9 reported gross assets on a filing in 2022 or later
Regulatory footprint (Form ADV)
- Adviser type
- registered investment adviser
- Form ADV filings
- Feb 13, 2012 to Oct 31, 2022
- RAUM
- $1.7Bregulatory assets under management of the adviser; not dry powder, not a fund size
- PE funds, latest filing
- 9
- PE fund GAV, latest filing
- $1.7Breported gross assets (Form ADV), not fund size
- All private fund GAV
- $1.7Bevery private fund type, latest filing
- 2024 PE fund GAV
- $57.5Msum over funds typed Private Equity Fund with a 2024 or later as-of date
- PE share of funds, lifetime
- 53%
- Fund type mix
- filed 2022-10-31, latest gav Private Equity Fund $1.7B, latest counts Private Equity Fund 9, lifetime distinct Hedge Fund 1, Private Equity Fund 9, Venture Capital Fund 7
- Employees
- 24
- Headquarters
- Menlo Park, CA
- Office address
- 3000 SAND HILL ROAD, B1-145, Menlo Park, CA, 94025
- Business phone
- 650 926 0600
Stated criteria beside observed behaviour
1 observed deals
Stated by the firm
- Sectors
- technology
- Geography
- not stated or not yet read
- Revenue
- not stated or not yet read
- EBITDA
- not stated or not yet read
- Enterprise value
- not stated or not yet read
- Equity check
- from $30.0M
- Control
- not stated or not yet read
- Thesis
- Innovation is of course the hallmark of the companies in which we invest, but also of A••••••••• itself.
Observed from deals on record
- roles
- unknown 1
- period
- to unknown, from unknown, undated holdings 1, dated observations 0
- window
- last unknown, first unknown
- control
- unknown 1
- companies
- 1
- geography
- investments
- 1
- seller kinds
- transactions
- 0
- cadence by year
- platform add on
- add ons 0, platforms 0, add ons per platform unknown
- sector known for
- 0
- disclosed value usd
- n 0
- sector distribution
- holding period years
- n 0
- repeat counterparties
- subsector distribution
1 companies on the graph (0 transactions); no dated observations
Funds
10 on record
| Fund | Vehicle | Vintage | Reported gross assets (Form ADV), not fund size | GAV by year | Form D sold | Lifecycle |
|---|---|---|---|---|---|---|
| A••••••••• C••••••• C••••••••• C••••••••• F••• ADV: Private Equity Fund | buyout or unlabelled | 2024 first reported on Form ADV | $57.5M as of Jul 3, 2024 | no Form D | Unknown | |
| A••••••••• C••••••• C••••••••• F••• 2• L• ADV: Private Equity Fund | buyout or unlabelled | 2021 first reported on Form ADV | $573M as of Oct 31, 2022 | no Form D | Unknown | |
| A••••••••• C••••••• C••••••••• F••• 2• C••••••••• L• ADV: Private Equity Fund | Co-investment vehicle | 2021 first reported on Form ADV | $24.8M as of Oct 31, 2022 | no Form D | Unknown | |
| A•• 8• S•••••••• U• L• ADV: Private Equity Fund | buyout or unlabelled | 2021 first reported on Form ADV | $7.5M as of Oct 31, 2022 | no Form D | Unknown | |
| A••••••••• B••••••••• 8• L• ADV: Private Equity Fund | buyout or unlabelled | 2020 first reported on Form ADV | $439M as of Oct 31, 2022 | no Form D | Harvest | |
| A••••••••• B••••••••• V•• L• ADV: Private Equity Fund | buyout or unlabelled | 2017 first reported on Form ADV | $304M as of Oct 31, 2022 | no Form D | Unknown | |
| A••••••••• C••••••• C••••••••• F••• L• ADV: Private Equity Fund | buyout or unlabelled | 2016 first reported on Form ADV | $125M as of Oct 31, 2022 | no Form D | Harvest | |
| A••••••••• B••••••••• V• L• ADV: Private Equity Fund | buyout or unlabelled | 2015 first reported on Form ADV | $232M as of Oct 31, 2022 | no Form D | Harvest | |
| A••••••••• B••••••••• V• L• ADV: Private Equity Fund | buyout or unlabelled | 2015 first reported on Form ADV | $15.0M as of Oct 31, 2022 | no Form D | Harvest | |
| A••••••••• B••••••••• V• C•••••••• G••••• E••••• F••• L• ADV: Private Equity Fund | Co-investment vehicle | 2015 first reported on Form ADV | $10.8M as of Oct 31, 2022 | no Form D | Mature |
Team
15 current, 14 former
Managing partner (1)
- K••••• H••• v•• E••••• · President/Director Of A••••••••• Management Inc · since Jan 1, 2015 SEC Form ADV filing data 2011 to 2024 (Schedule D 7.B.(1) private funds, Schedules A/B, 1.I websites)
Partner (2)
- K••• v•• E••••• · K••• v•• E•••••Managing Partner · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
- T•• H••••• · T•• H•••••Executive Partner · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
Principal (6)
- A••••• S••••••• · A••••• S•••••••Managing Director, Head of Publics & Late Stage · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
- J••••• P•••••• · J••••• P••••••Managing Director, Head of Venture · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
- N••• A••••• C••••• · Director Of A••••••••• Management Inc · since Dec 1, 2019 SEC Form ADV filing data 2011 to 2024 (Schedule D 7.B.(1) private funds, Schedules A/B, 1.I websites)
- R••••• D••••••••• · R••••• D•••••••••Managing Director, CCD · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
- T••••• W••••• · T••••• W•••••Managing Director, CCD · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
- V•••••• M•••• · V•••••• M••••Executive Director · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
Associate (2)
- A••• S••••• · A••• S•••••Senior Associate · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
- H•••• L•• · H•••• L••Senior Associate, CCD · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
Platform (2)
- E••• O••••••• · E••• O•••••••General Counsel · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
- J••• G•••••• H•••• · Cco/Secretary Of A••••••••• M••••••••• I••• · since Feb 1, 2007 SEC Form ADV filing data 2011 to 2024 (Schedule D 7.B.(1) private funds, Schedules A/B, 1.I websites)
Other (2)
- A•••• S••• · A•••• S•••Vice President, CCD · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
- B••• M••••••••• · B••• M•••••••••Global Head of Life Sciences & CIO · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
14 former (kept with end dates)
- K•••••• H••••• H••• · President/Director Of A••••••••• Management Inc · Feb 1, 2014 to Dec 21, 2019 Inference
- T•••••• J••• H••••• · Managing Partner Of A••••••••• L•• · Mar 1, 2008 to Sep 28, 2018 Inference
- M•••••• F•••••• B••••• · Onwer Of A••••••••• L•• · Dec 1, 2012 to Sep 30, 2016 Inference
- D•••• F•••••••• J•••• L••••••• · Owner Of A••••••••• Management Holdings Limited · Aug 1, 1989 to Nov 5, 2020 Inference
- J••••••• J•••• M•••••••• · Owner Of A••••••••• L•• · Dec 1, 2012 to Sep 30, 2016 Inference
- J••••• A••••••• · Partner Of A••••••••• L•• · Mar 1, 2008 to Sep 30, 2016 Inference
- Q•••••• L••••• G•••••• L••••••••• · Owner Of A••••••••• L•• · Mar 1, 2008 to Sep 2, 2022 Inference
- Q•••••• L••••• G•••••• L••••••••• · Partner Of A••••••••• L•• · Mar 1, 2008 to Sep 28, 2018 Inference
- S•••••• W•••••• B•••••• · Owner Of A••••••••• Management Holdings Limited · Aug 1, 1989 to Nov 5, 2020 Inference
- T•••••• J••• H••••• · Owner Of A••••••••• L•• · Mar 1, 2008 to Sep 2, 2022 Inference
- B•••• M•••••• G•••••••• · Treasurer/Director Of A••••••••• Management Inc · Dec 1, 2019 to Sep 2, 2022 Inference
- J•••• F••••• A•••• · Director Of A••••••••• Management Inc · Sep 1, 2000 to Dec 21, 2019 Inference
- J••••••• J•••• M•••••••• · Director · May 1, 1999 to Sep 26, 2014 Inference
- M•••••• F•••••• B••••• · Director · Apr 1, 2003 to Feb 26, 2015 Inference
Portfolio
1 relationships, 0 platforms, 0 add-ons
| Company | Role | Status | Invested | Held | Partner | Source |
|---|---|---|---|---|---|---|
| E•••• | Role unknown | unknown | unknown | unknown | unknown | Fact Investment organization websites (team, portfolio, strategy, criteria, news) |
Transactions
0 on record
No transaction naming this firm has been collected yet. The deal tape is read from SEC filings and cited announcements.
Placement agents, lenders, advisers and co-investors
2 relationships
Placement agents (2)
- A••••• C•••••• G•••• A••••••• L•• 2 shared · recurring · last Jan 1, 2020
- T•• C•••••• M•••••• L••••• 1 shared · one time · last Jan 1, 2024
LP commitments
0 disclosed
No LP commitment collected yet. An LP edge needs a public disclosure with a quote, such as a pension plan’s report or an announcement naming the LP.
Events
60 most recent
- Sep 1, 2026Adviser CRD 157466 is not on the SEC registered or exempt adviser roster of 2026-09-01
- Aug 28, 202628 August 2026Redx Announces Close of Series A Financing of $36 Million and Strengthened Board Composition
- Jul 20, 202620 July 2026Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
- Jul 15, 202615 July 2026AdvanCell Closes US $315 Million Oversubscribed Series D Financing to Advance Targeted Alpha Therapies and Expand C••••••• and Commercial Manufacturing Infrastructure
- Jul 8, 20268 July 2026Allotera Therapeutics (Formerly Wugen) Closes $35 Million Financing to Advance Off-the-Shelf CAR-T Therapies for T-Cell Cancers
- Jul 6, 20266 July 2026Myricx Bio to be Acquired by Novartis to Advance Next-Generation ADC Payloads for Oncology with Novel NMTi Platform
- Apr 6, 20266 April 2026Neurocrine to Acquire Soleno Therapeutics
- Jan 7, 20267 January 2026Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of C••••••• G•••••
- Nov 17, 202517 November 2025AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global G•••••
- Sep 22, 202522 September 2025ADC Innovator Myricx Bio Appoints Boston-based Mohit Rawat as CEO and Expands Team in US and UK
- Jul 9, 20259 July 2025Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive G••••• into the Next Decade
- Mar 5, 20255 March 2025Ascend Advanced Therapies appoints J••• Chiminski as Chair & Karen Flynn as Independent Director
- Feb 3, 20253 February 2025AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing
- Jan 13, 202513 January 2025Lilly to acquire Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program
- Jan 6, 20256 January 2025Iambic Therapeutics Appoints M•••••• Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer
- Nov 12, 202412 November 2024Ascend Advanced Therapies Partners with EW Healthcare Partners to Expand United States Capacity and Capabilities
- Sep 24, 202424 September 2024Ascend Advanced Therapies: Continued Investment in Technology & Flexible Capacity Includes New Fill/Finish Capabilities
- Sep 10, 202410 September 2024A••••••••• appoints R••••• D••••••••• as Managing Director – C••••••• C•••••••••
- May 13, 202413 May 2024Reneo Pharmaceuticals And OnKure Announce Proposed Merger
- Apr 23, 202423 April 2024Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-In-Class Oral MRGPR Antagonists
- Apr 9, 20249 April 2024Ascend acquires GMP manufacturing capacity in Alachua, Florida from Beacon Therapeutics
- Mar 25, 202425 March 2024Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
- Mar 13, 202413 March 2024Novartis Acquires IFM Due to Develop First-In-Class STING Antagonist Program Targeting Innate Immune System
- Feb 12, 202412 February 2024Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
- Jan 5, 20245 January 2024Scorpion Therapeutics Appoints Adam Friedman, M.D., Ph.D., as Chief Executive Officer and Expands Leadership Team
- Nov 16, 202316 November 2023Q32 Bio and Homology Medicines Announce Merger Agreement
- Oct 30, 202330 October 2023A••••••••• raises $356 million for new C••••••• C••••••••• C••••••••• Fund (CCD-CIF)
- Oct 3, 20233 October 2023Iambic Therapeutics Announces Close of Oversubscribed $100 Million Series B Financing to Advance AI-Discovered Therapeutics into C••••••• Development and Enters Collaboration with NVIDIA
- Sep 21, 202321 September 2023Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.
- May 10, 202310 May 2023Wugen Appoints Industry Leader Mark Alles as Chair of the Board of Directors
- Dec 13, 202213 December 2022A••••••••• appoints experienced life sciences investor Joy Ghosh, PhD as Managing Director
- Oct 18, 202218 October 2022Anjarium Biosciences Appoints Gaurav S••• as Chairperson and Douglas Fambrough as Non-executive Director
- Aug 15, 202215 August 2022Launch Therapeutics partners with Opthea to advance OPT-302, a promising therapy for wet AMD
- Aug 3, 20223 August 2022C•••••• Completes Acquisition of A••••••••• and Announces Go-forward Leadership Team; Acquisition Expands Global Healthcare Franchise with Leading Life Sciences Investment Expertise
- Jul 12, 202212 July 2022Anjarium Biosciences appoints experienced industry executives Samantha Vieira as Chief Operating Officer and Nate Massari as Chief Business Officer
- Jul 11, 202211 July 2022Glycomine Appoints Steven Axon as CEO and Adds Two New Board Directors
- Jul 1, 20221 July 2022GSK completes acquisition of Sierra Oncology
- Jun 14, 202214 June 2022Anjarium Biosciences appoints S•••••• Yoo, MD as Chief Executive Officer
- Apr 13, 202213 April 2022GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9bn
- Jan 10, 202210 January 2022Second A••••••••• gamma delta T cell company, Adaptate Biotherapeutics, to be acquired by Takeda
- Jan 5, 20225 January 2022SPRUCE BIOSCIENCES APPOINTS JAVIER SZWARCBERG, M.D., MPH AS CHIEF EXECUTIVE OFFICER
- Dec 17, 202117 December 2021Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients
- Nov 18, 202118 November 2021Novo Nordisk to Acquire Dicerna
- Nov 8, 20218 November 2021A••••••••• appoints J••••• P•••••• as Partner
- Oct 27, 202127 October 2021A••••••••• portfolio company GammaDelta Therapeutics to be acquired by Takeda
- Sep 24, 202124 September 2021Jasper Therapeutics Closes Transaction With Amplitude Healthcare Acquisition Corporation, Creating a Publicly Traded Biotechnology Company Dedicated to Enabling Cures Through Hematopoietic Stem Cell Therapy
- Sep 20, 202120 September 2021Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Two New Board Members
- Sep 15, 202115 September 2021A••••••••• strengthens investment team with new appointments in the US and UK
- Sep 8, 20218 September 2021HilleVax Closes $135 Million Crossover Financing to Advance C••••••• Stage Norovirus Vaccine Candidate
- Aug 10, 202110 August 2021NuCana Appoints Jeffrey D. Bloss, M.D. as Chief Medical Officer
- Jun 23, 202123 June 2021Glycomine Closes $68 Million Series B to Advance into C••••••• Trials a Novel Treatment for PMM2-CDG, a Rare Glycosylation Disease
- Jun 14, 202114 June 2021We are pleased to share Atsena Therapeutics has appointed Kenji Fujita, MD, as Chief Medical Officer
- May 27, 202127 May 2021eFFECTOR Therapeutics and Locust Walk Acquisition Corp. announce merger agreement to create publicly listed, next-generation oncology company developing new class of cancer therapies
- May 13, 202113 May 2021Congratulations B•••• Bock, newly appointed CFO of Exicure
- May 6, 20216 May 2021Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Merger to Create a Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation
- Mar 23, 202123 March 2021Delighted to share Reneo Pharmaceuticals has appointed Vineet R. Jindal as Chief Financial Officer
- Mar 15, 202115 March 2021Pleased to announce Reneo Pharmaceuticals has appointed Eric Dube, Ph.D. to its Board of Directors
- Mar 9, 20219 March 2021We are delighted that Q32 Bio has appointed Dr. Jason Campagna as Chief Medical Officer
- Mar 5, 20215 March 2021Adicet Bio Appoints Dr. A••••• S••••••• to its Board of Directors
- Jan 21, 202121 January 2021Trishula Therapeutics Appoints Anil Singhal as Chief Executive Officer
Across the graphs
A••••••••• M••••••••• I••• is the same institution as 2 records in Venture Capital and RIA and Wealth.
Venture Capital1RIA and Wealth1
Which record it is in each graph, what it is called there, and what the two were joined on. The Data Factory holds all nine graphs and the identity layer between them.
Checking your plan…